main-image-padlock

Padlock Therapeutics

In March 2016 Bristol-Myers Squibb (NYSE:BMY) agreed to acquire Padlock to continue the development of medicines targeting protein-arginine deiminases (PADs), enzymes with an important role in the generation of autoantigens, inflammation, and immune complex formation in autoimmune diseases.

Headquarters Cambridge, MA
Website www.padlocktx.com​
Twitter @PadlockTx​
Pipeline Preclinical
Partners GlaxoSmithKline